Prognostic factors in childhood acute lymphoblastic leukemia
- Martin Schrappe
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Approximately 80% of children and adolsecents with acute lymphoblastic leukemia (ALL) can be cured. To reduce the rate of relapses, but also to limit treatment toxicity, risk-adapted treatment has been attempted after identifying the most specific prognostic factors. In addition to clinical factors such as age and WBC, or factors of the leukemic cell such as the immunphenotype and the cytogenetics, thein vivo response to therapy has evolved as the most important predictor for relapse. The lack of specificity of most prognostic factors stimulated the search for more relevant parameters. Detection of residual disease at defined timepoints by cytomorphology can provide specific prognostic information, which allows to define new risk groups. Detection of minimal residual disease (MRD) by identifying clone-specific T-cell receptor-(TCR) or immunglobuline (Ig) gene rearrangements is currently being evaluated to extend this approach of testing the individual’s sucsceptibility to therapy. The high sensitivity of the method when indicating fast clearance of leukemia might eventually spare some patients of inadequately toxic therapy. Persistent disease is an indication for treatment modification and intensification. If standardized tools are used for treatment response evaluation, logistics and quality controls are demanding but essential for the reliable conduct of such clinical studies.
- Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze Get al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.Blood 1994; 84: 3122–3133.
- Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton Vet al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85–01.J Clin Oncol 1994; 12: 740–747.
- Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X.Lancet 1995; 345:143–148. CrossRef
- Pui CH. Childhood leukemias.N Engl J Med 1995; 332: 1618–1630. CrossRef
- Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JNet al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.N Engl J Med 1998; 338:1663–1671. CrossRef
- Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze Get al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995.Leukemia 2000; 14:2205–2222. CrossRef
- Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer Det al. Results and significance of six randomized trials in four consecutive ALL-BFM trials.Haematol Blood Transfus 1990; 33: 439–450.
- Tubergen IDG, Gilchrist GS, O’Brien RT, Coccia PF, Sather HN, Waskerwitz MJet al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.J Clin Oncol 1993; 11: 527–537.
- Schrappe M, Reiter A, Riehm H. Prophylaxis and treatment of meningeosis in childhood acute lymphoblastic leukemia.J Neuro-Oncol 1998; 38:159–165. CrossRef
- Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein Het al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) [The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83).Klin Pädiatr 1987; 199:151–160. CrossRef
- Schrappe M, Reiter A, Ludwig W-D, Harbott J, Zimmermann M, Hiddemann Wet al. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: Results of trial ALL-BFM 90.Blood 2000; 95: 3310–3322.
- Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JTet al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia.Blood 1995; 86:1292–1295.
- Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JHet al. Cytoreduction and prognosis in acute lymphoblastic leukemia – the importance of early marrow response: report from the Childrens Cancer Group.J Clin Oncol 1996; 14:389–398.
- Gaynon PS, Desai AA, Bostrom BC, Hutchinson R, Lange BJ, Nachman JBet al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review.Cancer 1997; 80:1717–1726. CrossRef
- Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SCet al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.Lancet 1998; 351: 550–554. CrossRef
- Van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral Let al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: A prospective study of the International BFM Study Group.Lancet 1998; 352:1731–1738. CrossRef
- Biondi A, Valsecchi MG, Seriu T, d’Aniello E, Willemse MJ, Fasching Ket al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.Leukemia 2000; 14:1939–1943. CrossRef
- Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.Blood 2000; 95: 790–794.
- Zur Stadt U, Harms DO, Schluter S, Schrappe M, Goebel U, Spaar Het al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen.Leukemia 2001; 15:283–285. CrossRef
- Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen Net al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.Blood 2002; 99:1253–1258. CrossRef
- Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon Pet al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.J Clin Oncol 1996; 14:18–24.
- Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JWG, Ratei Ret al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92.Leukemia 1996; 10: 957–963.
- Schrappe M, Reiter A, Harbott J, Zimmermann M, Henze G, Boos Jet al. Improved Risk-Adapted Treatment of Childhood ALL with a New Stratification System Based on Early Response, Genetics, Age, and WBC: First Interim Analysis of Trial ALL-BFM 95.Blood 2001; 98: 718a
- Aricò, M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina Cet al. Improved outcome in high risk childhood acute lymphoblastic leukemia defined by prednisone poor response treated with double BFM Protocol II.Blood 2002; 100: 420–426. CrossRef
- Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JSet al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response.Leukemia 1997; 11: 1732–1741. CrossRef
- Seriu T, Erz D, Stark Y, Bartram CR. T cell receptor Ddelta2Ddelta3 rearrangement: a suitable allele-specific marker for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.Leukemia 1997; 11: 759–761. CrossRef
- Willemse MJ, Seriu T, Hettinger K, d’Aniello E, Hop WC, Panzer-Grumayer ERet al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-AI.L.Blood 2002; 99 (12): 4386–4393. CrossRef
- Cave H, van derWerff ten Bosch J, Suciu S, Guidai C, Waterkeyn C, Otten Jet al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer — Childhood Leukemia Cooperative Group.N Engl J Med 1998; 339 (9): 591–598. CrossRef
- Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger Net al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.Blood 2002; 99 (6): 1952–1958. CrossRef
- Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZet al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.J Clin Oncol 1993; 11: 2234–2242.
- Riehm H, Gadner H, Henze G, Langermann H-J, Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976.Am J Pediatr Hematol Oncol 1980; 2:299–306.
- Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann Met al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.Blood 2000; 95:416–421.
- Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter Vet al. Ph+ childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.Blood 1998; 92: 2730–2741.
- Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel Aet al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.N Engl J Med 2000; 342 (14): 998–1006. CrossRef
- Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps Wet al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.Lancet 2002; 359 (9321): 1909–1915. CrossRef
- Bührer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub Get al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome.J Clin Oncol 1996; 14: 2812–2817.
- Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann Bet al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia.Lancet 2001; 358:1239–1241. CrossRef
- Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials.Br J Haematol 1995; 89:364–372.
- Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman Pet al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.Med Pediatr Oncol 1990; 18: 273–279. CrossRef
- Doerdelmann M, Reiter A, Borkhardt A, Ludwig W-D, Götz N, Viehmann Set al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.Blood 1999; 94:1209–1217.
- Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze Get al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.Blood 1992; 80: 2471–2478.
- Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann Met al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90.Blood 1999; 94: 3294–3306.
- Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. More is better! Update of Dana-Farber Cancer Institute/Children’s Hospital childhood acute lymphoblastic leukemia trials.Haematol Blood Transfus 1990; 33:459–466.
- Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch Met al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy.Lancet 1991; 337:61–66. CrossRef
- Prognostic factors in childhood acute lymphoblastic leukemia
The Indian Journal of Pediatrics
Volume 70, Issue 10 , pp 817-824
- Cover Date
- Print ISSN
- Online ISSN
- Springer India
- Additional Links
- Childhood ALL
- Prognostic factors
- Treatment response
- Industry Sectors
- Martin Schrappe (1)
- Author Affiliations
- 1. Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany